Search This Blog

Friday, October 7, 2022

Oramed: Unit Has Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

 

  • Primary and secondary endpoints of safety and immunogenicity met

  • Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline

  • Trial shows proof of concept for oral delivery of vaccines using Oravax technology

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)